BibTex RIS Kaynak Göster

Sensorineural type hearing loss with pegylated interferon alfa/ribavirin therapy

Yıl 2013, Cilt: 2 Sayı: 3, 248 - 249, 01.09.2013

Oğuz Karabay Mehmet Güven Aziz Öğütlü Süleyman Cesur Deniz Gin Nazan Tuna

https://doi.org/10.5505/abantmedj.2013.44153

Kaynakça

  • Howaizi M. Pegylated interferon-induced eyelid and eye- brow trichomegaly during chronic hepatitis C. J Gastroenterol Hepatol 2005; 20: 1945–1946.
  • Goksugur N, Karabay O. Eyelash and eyebrow trichomegaly induced by interferon-alfa 2a. Clin Exp Dermatol 2007; 32: 583–584.
  • Karabay O, Goksugur N, Ogutlu A. Tongue hyperpigmentation during interferon therapy. Journal of Dermatology. 2011; 38: 290-291.
  • Johnson K, Sargent LA, Galizio C, Ubogu EU. Interferon- alfa-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. Eur J Gastroenterol Hepatol 2008; 20: 1110-1114.
  • Atuğ O, Akın H, Yılmaz Y, Sarı M, Tozun N. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C. J Gastrointestin Liver Dis 2009; 18: 256.
  • Elloumi H, Houissa F, Hadj BN, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden hearing loss associated with peginterferon and ribavirin combination theraphy during hepatitis C treatment. World J gastroenterol 2007; 28: 5411-5412.
  • Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, Gangl A, Ferenci P. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004; 99: 873–877.
  • Wong VK, Cheong-Lee C, Ford JA, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination theraphy during hepatitis C treatment: Outcome after resumption of theraphy. World J Gastroenterol 2005; 11: 5392-5393.
  • Piekarska A, Jozefowicz-Korczynska M, Wojcik K, Berkan E. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin. Int J Audiol 2007; 46(7): 345-350.
  • Hagr A, Jamjoom D, Sanai F.M, Al Hamoudi W, Abdo A.A, Al-Arfaj A. Effect of interferon treatment on hearing of patients with chronic Hepatitis C. Saudi J Gastroenterol 2011; 2: 114-118.
  • Akyol MU, Sarac S, Akyol G, Atac A, Poyraz A, Belgin E, Turan E. Investigation of the ototoxic effects of interferon alpha2A on the mouse cochlea Otolaryngol Head Neck Surg 2001 ;124(1): 107-110.

Pegile İnterferon alfa/ribavirin tedaviyle gelişen sensorinöral tipte işitme kaybı

Yıl 2013, Cilt: 2 Sayı: 3, 248 - 249, 01.09.2013

Oğuz Karabay Mehmet Güven Aziz Öğütlü Süleyman Cesur Deniz Gin Nazan Tuna

https://doi.org/10.5505/abantmedj.2013.44153

Kaynakça

  • Howaizi M. Pegylated interferon-induced eyelid and eye- brow trichomegaly during chronic hepatitis C. J Gastroenterol Hepatol 2005; 20: 1945–1946.
  • Goksugur N, Karabay O. Eyelash and eyebrow trichomegaly induced by interferon-alfa 2a. Clin Exp Dermatol 2007; 32: 583–584.
  • Karabay O, Goksugur N, Ogutlu A. Tongue hyperpigmentation during interferon therapy. Journal of Dermatology. 2011; 38: 290-291.
  • Johnson K, Sargent LA, Galizio C, Ubogu EU. Interferon- alfa-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. Eur J Gastroenterol Hepatol 2008; 20: 1110-1114.
  • Atuğ O, Akın H, Yılmaz Y, Sarı M, Tozun N. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C. J Gastrointestin Liver Dis 2009; 18: 256.
  • Elloumi H, Houissa F, Hadj BN, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden hearing loss associated with peginterferon and ribavirin combination theraphy during hepatitis C treatment. World J gastroenterol 2007; 28: 5411-5412.
  • Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, Gangl A, Ferenci P. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004; 99: 873–877.
  • Wong VK, Cheong-Lee C, Ford JA, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination theraphy during hepatitis C treatment: Outcome after resumption of theraphy. World J Gastroenterol 2005; 11: 5392-5393.
  • Piekarska A, Jozefowicz-Korczynska M, Wojcik K, Berkan E. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin. Int J Audiol 2007; 46(7): 345-350.
  • Hagr A, Jamjoom D, Sanai F.M, Al Hamoudi W, Abdo A.A, Al-Arfaj A. Effect of interferon treatment on hearing of patients with chronic Hepatitis C. Saudi J Gastroenterol 2011; 2: 114-118.
  • Akyol MU, Sarac S, Akyol G, Atac A, Poyraz A, Belgin E, Turan E. Investigation of the ototoxic effects of interferon alpha2A on the mouse cochlea Otolaryngol Head Neck Surg 2001 ;124(1): 107-110.
Toplam 11 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Editöre Mektup
Yazarlar

Oğuz Karabay Bu kişi benim

Mehmet Güven Bu kişi benim

Aziz Öğütlü Bu kişi benim

Süleyman Cesur Bu kişi benim

Deniz Gin Bu kişi benim

Nazan Tuna Bu kişi benim

Yayımlanma Tarihi 1 Eylül 2013
Yayımlandığı Sayı Yıl 2013 Cilt: 2 Sayı: 3

Kaynak Göster

APA Karabay, O., Güven, M., Öğütlü, A., Cesur, S., vd. (2013). Pegile İnterferon alfa/ribavirin tedaviyle gelişen sensorinöral tipte işitme kaybı. Abant Medical Journal, 2(3), 248-249. https://doi.org/10.5505/abantmedj.2013.44153
AMA Karabay O, Güven M, Öğütlü A, Cesur S, Gin D, Tuna N. Pegile İnterferon alfa/ribavirin tedaviyle gelişen sensorinöral tipte işitme kaybı. Abant Med J. Eylül 2013;2(3):248-249. doi:10.5505/abantmedj.2013.44153
Chicago Karabay, Oğuz, Mehmet Güven, Aziz Öğütlü, Süleyman Cesur, Deniz Gin, ve Nazan Tuna. “Pegile İnterferon alfa/Ribavirin Tedaviyle gelişen sensorinöral Tipte işitme Kaybı”. Abant Medical Journal 2, sy. 3 (Eylül 2013): 248-49. https://doi.org/10.5505/abantmedj.2013.44153.
EndNote Karabay O, Güven M, Öğütlü A, Cesur S, Gin D, Tuna N (01 Eylül 2013) Pegile İnterferon alfa/ribavirin tedaviyle gelişen sensorinöral tipte işitme kaybı. Abant Medical Journal 2 3 248–249.
IEEE O. Karabay, M. Güven, A. Öğütlü, S. Cesur, D. Gin, ve N. Tuna, “Pegile İnterferon alfa/ribavirin tedaviyle gelişen sensorinöral tipte işitme kaybı”, Abant Med J, c. 2, sy. 3, ss. 248–249, 2013, doi: 10.5505/abantmedj.2013.44153.
ISNAD Karabay, Oğuz vd. “Pegile İnterferon alfa/Ribavirin Tedaviyle gelişen sensorinöral Tipte işitme Kaybı”. Abant Medical Journal 2/3 (Eylül 2013), 248-249. https://doi.org/10.5505/abantmedj.2013.44153.
JAMA Karabay O, Güven M, Öğütlü A, Cesur S, Gin D, Tuna N. Pegile İnterferon alfa/ribavirin tedaviyle gelişen sensorinöral tipte işitme kaybı. Abant Med J. 2013;2:248–249.
MLA Karabay, Oğuz vd. “Pegile İnterferon alfa/Ribavirin Tedaviyle gelişen sensorinöral Tipte işitme Kaybı”. Abant Medical Journal, c. 2, sy. 3, 2013, ss. 248-9, doi:10.5505/abantmedj.2013.44153.
Vancouver Karabay O, Güven M, Öğütlü A, Cesur S, Gin D, Tuna N. Pegile İnterferon alfa/ribavirin tedaviyle gelişen sensorinöral tipte işitme kaybı. Abant Med J. 2013;2(3):248-9.